New pill shows promise against Hard-to-Treat cancers
NCT ID NCT06264921
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 32 times
Summary
This early-phase study tested a new daily pill, NKT3447, in 23 adults with advanced solid tumors (like ovarian, endometrial, or lung cancer) that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AdventHealth Cancer Institute
Celebration, Florida, 34747, United States
-
Augusta University Georgia Cancer Center
Augusta, Georgia, 30909, United States
-
Norton Cancer Institute - Broadway
Louisville, Kentucky, 40202, United States
-
START Mountain Region
West Valley City, Utah, 84119, United States
-
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, 80218, United States
-
Texas Oncology-Austin Midtown NEXT Oncology
Austin, Texas, 78758, United States
-
The Gabrail Pharmacology Phase 1 Research Center
Canton, Ohio, 44718, United States
-
University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158, United States
Conditions
Explore the condition pages connected to this study.